Compare Elan Corp. with Similar Stocks
Dashboard
1
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 24.54%
- Healthy long term growth as Net Sales has grown by an annual rate of 15.53% and Operating profit at 14.47%
- Company has very low debt and has enough cash to service the debt requirements
2
With ROE of 20.37%, it has a very attractive valuation with a 3.01 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
JPY 47,450 Million (Small Cap)
15.00
NA
0.00%
-0.34
20.37%
3.27
Revenue and Profits:
Net Sales:
14,763 Million
(Quarterly Results - Jun 2026)
Net Profit:
793 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
10.68%
0%
10.68%
6 Months
9.26%
0%
9.26%
1 Year
-4.24%
0%
-4.24%
2 Years
-2.42%
0%
-2.42%
3 Years
-5.89%
0%
-5.89%
4 Years
-33.59%
0%
-33.59%
5 Years
-34.05%
0%
-34.05%
Elan Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
15.53%
EBIT Growth (5y)
14.47%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.37
Sales to Capital Employed (avg)
3.80
Tax Ratio
32.88%
Dividend Payout Ratio
32.77%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
72.95%
ROE (avg)
24.54%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
3.01
EV to EBIT
8.55
EV to EBITDA
6.91
EV to Capital Employed
4.04
EV to Sales
0.68
PEG Ratio
0.68
Dividend Yield
NA
ROCE (Latest)
47.26%
ROE (Latest)
20.37%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
14,763.00
13,406.90
10.11%
Operating Profit (PBDIT) excl Other Income
1,315.10
1,256.00
4.71%
Interest
14.10
10.50
34.29%
Exceptional Items
0.00
0.00
Consolidate Net Profit
793.30
579.90
36.80%
Operating Profit Margin (Excl OI)
81.30%
66.20%
1.51%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 10.11% vs 18.04% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 36.80% vs -3.11% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
55,448.70
47,513.70
16.70%
Operating Profit (PBDIT) excl Other Income
5,573.10
4,509.80
23.58%
Interest
59.00
1.70
3,370.59%
Exceptional Items
13.30
0.00
Consolidate Net Profit
2,829.80
2,354.70
20.18%
Operating Profit Margin (Excl OI)
76.20%
75.60%
0.06%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 16.70% vs 14.70% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 20.18% vs -6.51% in Dec 2024
About Elan Corp. 
Elan Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






